Last reviewed · How we verify
FOLFOX/ FOLFIRI with bevacizumab
FOLFOX/FOLFIRI chemotherapy regimens combined with bevacizumab inhibit tumor cell division and block new blood vessel formation to starve tumors of nutrients.
FOLFOX/FOLFIRI chemotherapy regimens combined with bevacizumab inhibit tumor cell division and block new blood vessel formation to starve tumors of nutrients. Used for Metastatic colorectal cancer, First-line treatment of advanced colorectal cancer.
At a glance
| Generic name | FOLFOX/ FOLFIRI with bevacizumab |
|---|---|
| Also known as | - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin |
| Sponsor | Dutch Colorectal Cancer Group |
| Drug class | Chemotherapy combination with anti-angiogenic monoclonal antibody |
| Target | DNA (chemotherapy); VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) and FOLFIRI (5-fluorouracil, leucovorin, irinotecan) are cytotoxic chemotherapy combinations that damage DNA and inhibit cell proliferation. Bevacizumab is a monoclonal antibody targeting VEGF (vascular endothelial growth factor) that prevents angiogenesis, reducing blood supply to tumors and enhancing chemotherapy efficacy.
Approved indications
- Metastatic colorectal cancer
- First-line treatment of advanced colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Fatigue
- Peripheral neuropathy
- Hypertension
- Bleeding/hemorrhage
- Thromboembolism
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers (PHASE1)
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (PHASE1)
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis (EARLY_PHASE1)
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer (EARLY_PHASE1)
- Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFOX/ FOLFIRI with bevacizumab CI brief — competitive landscape report
- FOLFOX/ FOLFIRI with bevacizumab updates RSS · CI watch RSS
- Dutch Colorectal Cancer Group portfolio CI